US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

DexCom, Inc. - Common Stock (NQ:DXCM)

86.90 +1.54 (+1.80%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
50 51 Next >
News headline image
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market. ↗
Smart rings are one of the hottest consumer electronics categories, as evidenced by exhibitors at CES 2025. Oura leads the market. 
Via Investor's Business Daily
News headline image
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025 ↗
Via The Motley Fool
News headline image
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
News headline image
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 ↗
Via The Motley Fool
News headline image
NASDAQ:DXCM qualifies as a high growth stock and is consolidating. ↗
DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
1 Reason to Sell DexCom Stock, and 1 Reason to Buy ↗
Via The Motley Fool
News headline image
Peering Into DexCom's Recent Short Interest ↗
 
Via Benzinga
News headline image
Key Takeaways From DexCom Analyst Ratings ↗
 
Via Benzinga
News headline image
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
From DexCom, Inc.
Via Business Wire
News headline image
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos ↗
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
News headline image
3 Reasons to Buy DexCom Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Exploring the Growth Potential of NASDAQ:DXCM as It Nears a Breakout. ↗
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
News headline image
NASDAQ:DXCM qualifies as a high growth stock and is consolidating. ↗
Is DEXCOM INC (NASDAQ:DXCM) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
2 Excellent Healthcare Stocks to Hold Through the Next Decade ↗
Via The Motley Fool
News headline image
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗
Via The Motley Fool
News headline image
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest ↗
Via The Motley Fool
News headline image
Dexcom and ŌURA Announce Strategic Partnership
From DexCom, Inc.
Via Business Wire
News headline image
Analyst Expectations For DexCom's Future ↗
 
Via Benzinga
News headline image
These Analysts Revise Their Forecasts On DexCom Following Q3 Results ↗
 
Via Benzinga
News headline image
Large-Cap Stocks In Trouble - Sunday, Nov. 17 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
News headline image
Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom ↗
Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest Form 13F on Thursday and disclosed its trading activity from the prior quarter. 
Via Benzinga
News headline image
Dexcom Helps People With Diabetes Take the First Step to Discover What They’re Made Of on World Diabetes Day
From DexCom, Inc.
Via Business Wire
News headline image
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues ↗
Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024. 
Via Investor's Business Daily
News headline image
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years ↗
This medical device company is down but not out. 
Via The Motley Fool
News headline image
Why DexCom Stock Flopped on Friday ↗
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth. 
Via The Motley Fool
News headline image
Nasdaq Up Triple Digits As Stocks Rally, Yields Cool ↗
Stocks are finishing the week strong, but it's a pyrrhic victory, with two of the three major indexes still staring down sizable weekly losses. 
Via Talk Markets
News headline image
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗
The major indexes were mixed for the week. 
Via Investor's Business Daily
News headline image
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday? ↗
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks. 
Via Benzinga
News headline image
Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
50 51 Next >